T cell mediated immunity to Schistosoma japonicum infection and vaccination

Tebeje, Biniam Mathewos

doi:10.14264/uql.2019.969

Cited by 2 publications

(3 citation statements)

References 291 publications

(398 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A vaccine study conducted by immunizing sheep with radiated attenuated cercariae or schistosomula of Schistosoma mattheei generated a significant reduction (56-78%) in worm burden [125]. While a similar study using irradiated larval S. mansoni cercariae/schistosomula in baboons only resulted in a 20-30% reduction in worm and egg counts, in contrast, another study found that immunizing Cynomolgus monkeys with Cobalt 60 -irradiated schistosomula produced a 74% and 80% reduction in worm numbers and tissue egg burden, respectively [126][127][128]. The dose of radiation also has to be optimal so that parasites injected into the skin can exit through draining lymph nodes to the lungs, allowing for T cell recruitment [124].…”

Section: Radiation-attenuated Cercariae/schistosomula Vaccinesmentioning

confidence: 99%

“…An initial CD4 + T helper (Th) 1 immune response is generated against the migratory schistosomula, leading to the secretion of pro-inflammatory cytokines such as interferon (IFN)-γ, IL-1, IL-6, IL-12, and alpha Tumour Necrosis Factor (TNF-α) [42]. Following egg deposition, at approximately six to eight weeks after infection with S. japonicum, CD4 + -Th2 cells are activated [60]. IL-4, IL-5, and IL-13 are then released, recruiting pro-inflammatory monocytes, neutrophils, eosinophils, hepatic stellate cells (in the liver), and macrophages around the eggs to form granulomas, collagen deposition, and fibrosis, leading to the destruction of the eggs [34,[50][51][52][53][54].…”

Section: Life Cycle and Immunopathologymentioning

confidence: 99%

See 1 more Smart Citation

Transmission-Blocking Vaccines against Schistosomiasis Japonica

Zumuk,

Jones,

Navarro

et al. 2024

IJMS

View full text Add to dashboard Cite

Control of schistosomiasis japonica, endemic in Asia, including the Philippines, China, and Indonesia, is extremely challenging. Schistosoma japonicum is a highly pathogenic helminth parasite, with disease arising predominantly from an immune reaction to entrapped parasite eggs in tissues. Females of this species can generate 1000–2200 eggs per day, which is about 3- to 15-fold greater than the egg output of other schistosome species. Bovines (water buffalo and cattle) are the predominant definitive hosts and are estimated to generate up to 90% of parasite eggs released into the environment in rural endemic areas where these hosts and humans are present. Here, we highlight the necessity of developing veterinary transmission-blocking vaccines for bovines to better control the disease and review potential vaccine candidates. We also point out that the approach to producing efficacious transmission-blocking animal-based vaccines before moving on to human vaccines is crucial. This will result in effective and feasible public health outcomes in agreement with the One Health concept to achieve optimum health for people, animals, and the environment. Indeed, incorporating a veterinary-based transmission vaccine, coupled with interventions such as human mass drug administration, improved sanitation and hygiene, health education, and snail control, would be invaluable to eliminating zoonotic schistosomiasis.

show abstract

Section: Radiation-attenuated Cercariae/schistosomula Vaccinesmentioning

confidence: 99%

Section: Life Cycle and Immunopathologymentioning

confidence: 99%

Transmission-Blocking Vaccines against Schistosomiasis Japonica

Zumuk,

Jones,

Navarro

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Four principal species of Schistosoma account for human schistosomiasis, namely, Schistosoma mansoni, S. hematobium, S intercalatum and S. japonicum. The parasites have a complex life cycle that involves snails as intermediary hosts ( McManus et al, 2008;Tebeje et al; Following the model given in 3.1 above the life cycle stages that occur in humans are: the cercariae (the infective stage representing the source) the schistosomula, the adults (male and female) and the eggs (representing the sink) which are released into the environment through feces or urine. With four life cycle stages infecting the definitive host and in accordance with equation-3, the number of subunit vaccine components is given by…”

Section: Schistosomiasismentioning

confidence: 99%

A rational approach for predicting the minimum composition of anti-parasite sub-unit vaccines: a multiple target vaccine hypothesis

Titanji¹,

Dinga²,

Nyasa³

2018

J. Cam. Acad. Sci

View full text Add to dashboard Cite

The present article introduces a new concept, termed a multiple vaccine target hypothesis (MVTH) for determining the minimum number of vaccine targets (epitopes/antigens) necessary to construct a highly efficacious (greater than 90%) anti-parasite vaccine. Drawing inspiration from the Metabolic Control Analysis (MCA) and immunological reasoning it is proposed that for a multi-stage parasite an effective anti-parasite vaccine will necessarily act on more than one stage of the parasite in the definitive host. It is argued that the minimum number of sub-unit targets for a highly efficacious anti-parasite vaccine will vary from one parasite to the other and will be equal to twice the number of major parasite stages occurring in the human host. Quantitatively stated, C v =2n where C v the number of required targets is, and n represents the number of major parasite stages in the definitive host. Conditions when the value of C v may deviate from what is predicted by the formula given above are discussed. Extensive literature search on malaria, onchocerciasis and schistosomiasis sub-unit vaccine development suggests that subunit vaccines constructed from single components and directed to just one parasite stage are less efficacious that multivariate sub-unit vaccines, and obviously whole parasite vaccines. MVTH therefore provides a rational framework for constituting a sub-unit anti-parasite vaccine.

show abstract

T cell mediated immunity to Schistosoma japonicum infection and vaccination

Abstract: Replication-defective recombinant optimized SjTPI adenoviral vaccine RNAi: RNA interference rSj97: Recombinant Schistosoma japonicum paramyosin rSjTPI-LD1 Recombinant Schistosoma japonicum triose phosphate isomerase-ligand binding domain of insulin receptor 1

Cited by 2 publications

References 291 publications

Transmission-Blocking Vaccines against Schistosomiasis Japonica

Transmission-Blocking Vaccines against Schistosomiasis Japonica

A rational approach for predicting the minimum composition of anti-parasite sub-unit vaccines: a multiple target vaccine hypothesis

Contact Info

Product

Resources

About